Jamesb Tananbaum News Today

Kinnate Biopharma (NASDAQ:KNTE – Get Rating)‘s stock had its “maintains” rating reaffirmed by research analysts at 500.com in a research report issued on Thursday, Benzinga reports. Other analysts also recently issued reports about the company. The Goldman Sachs Group decreased their price target on Kinnate Biopharma from $29.00 to $26.00 and set a “buy” rating […]

Insider trading activity has always invited interest and controversy from investors and authorities.

Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 1,510,000 shares, a decline of 16.6% from the April 15th total of 1,810,000 shares. Approximately 6.9% of the shares of the company are sold […]

Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) Director James B. Tananbaum acquired 1,780,000 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was bought at an average price of $2.80 per share, with a total value of $4,984,000.00. Following the acquisition, the director now directly owns 3,525,957 shares in the […]

Kinnate Biopharma (NASDAQ:KNTE – Get Rating) is scheduled to announce its earnings results on Friday, May 12th. Kinnate Biopharma (NASDAQ:KNTE – Get Rating) last posted its quarterly earnings data on Wednesday, March 15th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02). On average, analysts […]